7132
document
Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy . Tropisetron and granisetron are selective serotonin ( 5-HT3 ) antagonists that have been proven effective in the prevention of nausea and vomiting in adults and children receiving cancer chemotherapy . This prospective , randomised study was designed to compare the efficacy of the two agents in the prevention of vomiting and nausea in children receiving highly emetogenic chemotherapy for various malignancies . A total of 51 children ( mean age : 7.7 +/- 4.8 year ) were studied in 133 chemotherapy cycles . In 66 chemotherapy cycles , the children received tropisetron as an antiemetic agent in a dose of 0.2 mg/kg/24 h intravenously and , in 67 cycles , they received granisetron 40 micrograms/kg/24 h intravenously before cytotoxic drug administration during the days they received chemotherapy . The response per 24 h of chemotherapy was defined as complete ( no nausea and vomiting ) , partial ( 1-4 events of vomiting and/or nausea ) , and failure ( more than 4 events of vomiting and/or nausea ) . Efficacy of antiemetic therapy was evaluated as acute ( Day 1 ) and overall was based on the worst day during the chemotherapy . Complete control of acute vomiting was achieved in 74 % of tropisetron and 88 % of granisetron patients ( P = 0.04 ) , and complete control of acute nausea in 56 % and 82 % respectively ( p = 0.002 ) . Overall response by means of complete control of both vomiting and nausea during the whole therapy period was 29 % of tropisetron group and 55 % of granisetron group ( p = 0.007 ) . The statistical analysis ( depending on the emetogenicity of the chemotherapy cycles ) showed increased efficacy of granisetron in highly ( grade 3 ) emetogenic chemotherapy cycles ( p = 0.002 ) , whereas there was no difference in the very highly emetogenic cycles ( p = 0.7 ) . Also , granisetron was found to be more effective than tropisetron , especially in patients heavier than 25 kg ( p = 0.02 ) . The adverse reactions were few and mild . There were no differences in the tolerability of the two antiemetic therapy modalities . In conclusion , granisetron was found to be more effective than tropisetron in controlling nausea and vomiting in children receiving highly emetogenic chemotherapy . This increased antiemetic efficacy of ganisetron might have been related to maximal dose differences according to body weight .
7133
Intervention_Pharmacological
tropisetron and granisetron
7134
Intervention_Pharmacological
Tropisetron
7135
Intervention_Pharmacological
granisetron
7136
Intervention_Pharmacological
tropisetron
7137
Intervention_Pharmacological
granisetron
7138
Intervention_Pharmacological
chemotherapy
7139
Intervention_Physical
.
7140
Intervention_Pharmacological
tropisetron
7141
Intervention_Pharmacological
granisetron
7142
Intervention_Pharmacological
tropisetron
7143
Intervention_Pharmacological
granisetron
7144
Intervention_Pharmacological
granisetron
7145
Intervention_Pharmacological
tropisetron
7146
Intervention_Pharmacological
granisetron
7147
Intervention_Pharmacological
ganisetron
7148
Outcome_Adverse-effects
nausea and vomiting
7149
Outcome_Adverse-effects
nausea
7150
Outcome_Adverse-effects
vomiting
7151
Outcome_Adverse-effects
vomiting and nausea
7152
Outcome_Adverse-effects
Complete control of acute vomiting
7153
Outcome_Adverse-effects
acute nausea
7154
Outcome_Physical
Overall response
7155
Outcome_Adverse-effects
vomiting
7156
Outcome_Adverse-effects
nausea
7157
Outcome_Other
effective
7158
Outcome_Adverse-effects
adverse reactions
7159
Outcome_Other
tolerability
7160
Outcome_Adverse-effects
nausea
7161
Outcome_Adverse-effects
vomiting
7162
Outcome_Other
antiemetic efficacy
7163
Outcome_Physical
body weight
7164
Participant_Age
children
7165
Participant_Condition
cancer chemotherapy
7166
Participant_Age
adults
7167
Participant_Age
children
7168
Participant_Condition
cancer chemotherapy
7169
Participant_Age
children
7170
Participant_Condition
highly emetogenic chemotherapy
7171
Participant_Condition
malignancies
7172
Participant_Sample-size
51
7173
Participant_Age
7.7 +/- 4.8 year
7174
Participant_Age
children
7175
Participant_Condition
highly emetogenic chemotherapy